WallStSmart

Perspective Therapeutics Inc. (CATX)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 3394560% more annual revenue ($20.98B vs $618,000). GEHC leads profitability with a 9.1% profit margin vs 0.0%. GEHC earns a higher WallStSmart Score of 57/100 (C).

CATX

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -0.43

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CATX2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

CATX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$335.30M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CATX

The strongest argument for CATX centers on Price/Book, Debt/Equity.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : CATX

The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

CATX carries more volatility with a beta of 1.73 — expect wider price swings.

GEHC is growing revenue faster at 7.4% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (57/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Perspective Therapeutics Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?